Cabaletta's Q2 Loss Narrows Marginally Amid R&D Cost Cuts

TL;DR

**Cabaletta's cash burn continues, making it a risky bet despite slight R&D cost cuts.**

AI Summary

Cabaletta Bio, Inc. reported a net loss of $28.9 million for the quarter ended June 30, 2025, a slight increase from the $28.0 million net loss in the same period of 2024. Research and development expenses decreased to $22.9 million for the quarter, down from $23.8 million in Q2 2024, primarily due to reduced manufacturing and clinical trial costs. General and administrative expenses remained relatively stable at $6.7 million compared to $6.6 million in Q2 2024. The company's cash and cash equivalents stood at $109.8 million as of June 30, 2025, a decrease from $138.7 million at December 31, 2024. Strategic outlook includes continued development of their CABA-201 program, with an 'At-The-Market' offering sales agreement generating $1.1 million in net proceeds during the first six months of 2025. The company also recognized $1.0 million in revenue from a license agreement with Nanjing Iaso Biotherapeutics Co., Ltd. for the six months ended June 30, 2025.

Why It Matters

Cabaletta Bio's continued net losses and reliance on equity financing highlight the inherent risks in early-stage biotech. For investors, the slight reduction in R&D expenses is a positive signal of cost management, but the shrinking cash reserves from $138.7 million to $109.8 million in six months underscore the need for future capital raises. Employees face ongoing pressure to deliver clinical milestones to secure the company's long-term viability. In a competitive landscape, Cabaletta's ability to advance its CABA-201 program efficiently will be crucial for attracting further investment and demonstrating value to the broader market.

Risk Assessment

Risk Level: high — The company reported a net loss of $28.9 million for Q2 2025 and a decrease in cash and cash equivalents from $138.7 million at December 31, 2024, to $109.8 million at June 30, 2025. This significant cash burn, coupled with the early stage of its clinical programs, indicates a high reliance on future financing to sustain operations.

Analyst Insight

Investors should monitor Cabaletta Bio's cash burn rate closely and evaluate the progress of its CABA-201 clinical program. Given the high risk and ongoing losses, consider a 'wait and see' approach until clearer clinical milestones or a more sustainable financial trajectory emerges.

Financial Highlights

debt To Equity

N/A

revenue

$1.0M

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$28.9M

eps

N/A

gross Margin

N/A

cash Position

$109.8M

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $28.9M — Net Loss (for the quarter ended June 30, 2025, compared to $28.0M in Q2 2024)
• $22.9M — Research and Development Expenses (for Q2 2025, down from $23.8M in Q2 2024)
• $6.7M — General and Administrative Expenses (for Q2 2025, compared to $6.6M in Q2 2024)
• $109.8M — Cash and Cash Equivalents (as of June 30, 2025, down from $138.7M at Dec 31, 2024)
• $1.1M — Net Proceeds from ATM Offering (generated during the first six months of 2025)
• $1.0M — Revenue from License Agreement (for the six months ended June 30, 2025)

Key Players & Entities

• Cabaletta Bio, Inc. (company) — filer of the 10-Q
• Nanjing Iaso Biotherapeutics Co., Ltd. (company) — license agreement partner
• Autolus Holdings (company) — mentioned in relation to a past agreement
• Oxford Biomedica (company) — mentioned in relation to a past agreement
• SEC (regulator) — recipient of the 10-Q filing

FAQ

Risk Factors

• Significant Net Losses and Cash Burn [high — financial]: Cabaletta Bio reported a net loss of $28.9 million for Q2 2025, an increase from $28.0 million in Q2 2024. The company's cash and cash equivalents decreased to $109.8 million as of June 30, 2025, from $138.7 million at the end of 2024, indicating a continued burn rate that may require future financing.
• Clinical Trial and Regulatory Approval Risks [high — regulatory]: The company's primary focus is on the development of its CABA-201 program. Delays or failures in clinical trials, or challenges in obtaining regulatory approval from bodies like the FDA, could significantly impact the company's ability to bring its therapies to market and generate future revenue.
• Manufacturing and Supply Chain Dependencies [medium — operational]: As a biotechnology company, Cabaletta Bio relies on complex manufacturing processes and potentially specialized supply chains for its cell therapies. Any disruptions or inefficiencies in these areas could lead to increased costs and delays in product development and commercialization.
• Competition in the Cell Therapy Market [medium — market]: The cell therapy landscape is highly competitive, with numerous companies developing innovative treatments. Cabaletta Bio faces competition from both established pharmaceutical companies and emerging biotechs, which could affect market share and pricing power.
• Reliance on External Financing [high — financial]: The company's cash position has decreased, and its continued operations and development programs are dependent on its ability to secure additional funding through equity offerings, debt financing, or strategic partnerships. Failure to secure adequate funding could jeopardize its ongoing research and development efforts.

Industry Context

Cabaletta Bio operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on cell therapies for autoimmune diseases. The industry is characterized by significant R&D investment, long development timelines, and high regulatory hurdles. Companies in this space often rely on strategic partnerships and external financing to advance their pipelines.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Cabaletta Bio is subject to stringent regulations from bodies like the FDA. Successful development and approval of its CABA-201 program are contingent on meeting rigorous safety and efficacy standards. Any delays or setbacks in the regulatory process could significantly impact the company's timeline and financial outlook.

What Investors Should Do

1. Monitor cash burn rate and future financing needs.
2. Closely follow clinical trial progress for CABA-201.
3. Evaluate competitive landscape and market adoption potential.

Key Dates

• 2025-06-30: Quarterly Report (10-Q) Filing — Provides updated financial performance and operational highlights for the second quarter of 2025.
• 2025-06-30: End of Q2 2025 — Reporting period for key financial metrics including net loss, R&D expenses, G&A expenses, and cash position.
• 2025-01-01: Start of ATM Offering Period — Generated $1.1 million in net proceeds during the first six months of 2025, indicating ongoing efforts to raise capital.
• 2025-06-30: License Agreement Revenue Recognition — Recognized $1.0 million in revenue from the Nanjing Iaso Biotherapeutics Co., Ltd. license agreement for the first six months of 2025.

Glossary

At-The-Market (ATM) Offering

A type of public offering where a company sells its shares directly into the existing stock market over a period of time, typically through an intermediary. (Cabaletta Bio utilized this to generate $1.1 million in proceeds, demonstrating a method for ongoing capital raising.)

CABA-201

Cabaletta Bio's lead product candidate, a CAR-T therapy designed to treat autoimmune diseases. (This program is central to the company's development strategy and future revenue potential.)

Net Loss

The total expenses of a company exceed its total revenues over a specific period. (Cabaletta Bio reported a net loss of $28.9 million for Q2 2025, highlighting its status as a development-stage company.)

Cash and Cash Equivalents

Highly liquid short-term investments that can be readily converted into cash. (The company's cash position of $109.8 million is crucial for funding its ongoing research and development activities.)

Year-Over-Year Comparison

Cabaletta Bio's Q2 2025 results show a slight increase in net loss to $28.9 million compared to $28.0 million in Q2 2024, despite a decrease in R&D expenses. The company's cash position has declined from $138.7 million at the end of 2024 to $109.8 million, indicating continued operational spending. While revenue from a license agreement and ATM offering provided some capital, the overall financial trend suggests ongoing reliance on funding to support its development pipeline.

Key Financial Figures

• $0.00001 — ch registered Common Stock, par value $0.00001 per share CABA The Nasdaq Global Se

Filing Documents

• caba-20250630.htm (10-Q) — 2712KB
• caba-ex10_1.htm (EX-10.1) — 464KB
• caba-ex31_1.htm (EX-31.1) — 18KB
• caba-ex31_2.htm (EX-31.2) — 18KB
• caba-ex32_1.htm (EX-32.1) — 11KB
• caba-ex32_2.htm (EX-32.2) — 11KB
• 0000950170-25-104573.txt ( ) — 9435KB
• caba-20250630.xsd (EX-101.SCH) — 1015KB
• caba-20250630_htm.xml (XML) — 1491KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 4 Condensed Consolidated Balance Sheets 4 Condensed Consolidated Statements of Operations and Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 8 Notes to Unaudited Condensed Consolidated Financial Statements 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 37 Item 4.

Controls and Procedures

Controls and Procedures 37 PART II. OTHER INFORMATION 38 Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 38 Item 2. Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 98 Item 3. Defaults Upon Senior Securities 98 Item 4. Mine Safety Disclosures 98 Item 5. Other Information 98 Item 6. Exhibits 99

Signatures

Signatures 100 i Summary of the Material and Other Risks Associated with Our Business We are a clinical-stage company with a limited operating history, have incurred significant losses since our inception, and anticipate that we will continue to incur significant losses for the foreseeable future. We are highly dependent on our relationships with University of Pennsylvania, or Penn, Minaris Advanced Therapies, LLC, or Minaris (f/k/a WuXi Advanced Therapies, Inc) and/or Lonza Houston Inc., or Lonza, for our current manufacturing needs for our Phase 1/2 RESET TM , or Restoring Self-Tolerance, clinical trials for resecabtagene autoleucel (rese-cel, formerly referred to as CABA-201) and our Phase 1 clinical trial of MuSK-CAART, or the MusCAARTes TM trial, and if manufacturing capacity at any of these manufacturing partners is reduced or otherwise delayed or limited, including due to legislative action, or if we, Penn, Minaris, Lonza or any third-party manufacturers encounter difficulties in manufacturing our product candidates, this could adversely impact the supply of product candidates for and enrollment in our trials. We are reliant on intellectual property licensed to us by Penn and Nanjing IASO Biotherapeutics Co., Ltd., or IASO, and termination of one of these license agreements would result in the loss of significant rights, which would have a material adverse effect on our business. If we are unable to obtain and maintain sufficient intellectual property protection for our current product candidates and technologies or any future product candidates, we may not be able to compete effectively in our markets. We will need to raise substantial additional funding before we can expect to complete development of any of our product candidates or generate any revenues from product sales. Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability. If we are unable to su

—FINANCI AL INFORMATION

PART I—FINANCI AL INFORMATION

Financi al Statements

Item 1. Financi al Statements. CABALETTA BIO, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) June 30, 2025 December 31, 2024 Assets (unaudited) Current assets: Cash and cash equivalents $ 145,612 $ 163,962 Short-term investments 49,070 — Prepaid expenses and other current assets 3,725 2,713 Total current assets 198,407 166,675 Property and equipment, net 2,374 2,743 Finance lease right-of-use assets 16,689 7,020 Operating lease right-of-use assets 4,528 6,315 Other assets 2,502 2,293 Total assets $ 224,500 $ 185,046 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 7,193 $ 4,923 Accrued and other current liabilities 13,933 12,188 Finance lease liabilities, current portion 16,428 5,989 Operating lease liabilities, current portion 3,986 3,986 Total current liabilities 41,540 27,086 Finance lease liabilities, net of current portion 3,899 3,241 Operating lease liabilities, net of current portion 580 2,384 Total liabilities 46,019 32,711 Commitments and contingencies (see Notes 5 and 6) Stockholders' equity: Preferred stock, $ 0.00001 par value: 10,000,000 shares authorized as of June 30, 2025 and December 31, 2024; no shares issued or outstanding at June 30, 2025 and December 31, 2024 — — Voting and non-voting common stock, $ 0.00001 par value: 300,000,000 ( 293,590,481 voting and 6,409,519 non-voting) shares authorized as of June 30, 2025 and 150,000,000 ( 143,590,481 voting and 6,409,519 non-voting) shares authorized as of December 31, 2024; 91,451,899 voting shares issued and outstanding as of June 30, 2025 and 50,743,101 voting shares issued and outstanding as of December 31, 2024 1 1 Additional paid-in capital 608,651 501,435 Accumulated other comprehensive income 1 — Accumulated deficit ( 430,172 ) ( 349,101 ) Total

View Full Filing

View this 10-Q filing on SEC EDGAR